Post-earnings recap
Reported
Tue, Feb 17, 2026
EPS actual
$-0.94
EPS est.
$-1.03
EPS surprise
+8.74%
1-day move
+1.62%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
IDEAYA Biosciences I reported a narrower-than-expected loss per share, which contributed to a positive stock reaction, rising 1.62%. While there was no revenue data or forward guidance, the management's comments indicated a focus on future developments in their pipeline. Investors may view the EPS beat as a sign of progress, even in the absence of detailed revenue figures.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.94 | N/A | +8.74% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. They maintained a cautious outlook without providing specific guidance.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.